ArticleFrontiers in oncology2024

Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study.

Shujing Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.